BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) research hub

A PHASE I/II, OPEN-LABEL, DOSE ESCALATION AND EXTENSION STUDY OF INTRAVESICAL ECISKAFUSP ALFA IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) IN PARTICIPANTS WITH BCG-UNRESPONSIVE HIGH- RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

This study is testing a new combination treatment for a type of bladder cancer that hasn't responded to previous treatment. It involves a new medicine called eciskafusp alfa given directly into the bladder, along with an existing treatment (BCG). Researchers want to see if it's safe and helps shrink the cancer.